



Jubilant Life Sciences Ltd
Regd. Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar-244 223 (U.P.)
Unaudited Financial Results for the Quarter and Half year ended 30th September, 2011

(₹ in Lacs)

Particulars	CONSOLIDATED RESULTS				
	Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)
	2011	2010	2011	2010	2011
Net sales/Income from operations	104808	85897	199237	167659	343340
Other Operating Income	200	131	619	230	883
Total income	105008	86028	199856	167889	344223
Total expenditure	86282	76131	167486	148684	306812
a) (Increase)/Decrease in stock in trade and work in progress	(4522)	876	(8723)	(1905)	(3880)
b) Purchase of traded goods	6554	4551	13139	10314	24007
c) Raw & process materials consumed	36657	27362	70235	55563	112943
d) Stores, spares, chemicals, catalyst & packing material consumed	5113	5068	10985	10433	21188
e) Power & fuel	5822	5368	11823	10521	22404
f) Other manufacturing expenses	2539	1851	4342	3289	6965
g) Staff cost	20603	18081	39579	35778	71842
h) Depreciation	5080	4926	10057	9768	18010
i) Other Expenditure (Selling, general & admin. Expenses-Including Exchange L	8436	8048	16049	14923	33333
Operating profit before Other Income & Interest	18726	9897	32370	19205	37411
Other Income	340	424	707	657	1296
Profit before Interest & Exceptional Items	19066	10321	33077	19862	38707
Interest (Net)	4969	2476	9307	4423	10506
Profit after Interest but before Exceptional Items	14097	7845	23770	15439	28201

(₹ in Lacs)

Particulars	CONSOLIDATED RESULTS				
	Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)
Exceptional items	4260	291	4678	2371	4142
Profit from Ordinary Activities before tax	9837	7554	19092	13068	24059
Tax Expenses (Net)	930	260	2446	838	1336
Net profit from Ordinary Activities after tax	8907	7294	16646	12230	22723
Extraordinary Items (net of tax expenses)	-	-	-	-	-
Minority Interest	971	(52)	998	(159)	(249)
Net profit after Minority Interest	7936	7346	15648	12389	22972
Paid-up share capital (Face value per share ₹ 1)	1593	1588	1593	1588	1593
Reserves (excluding revaluation reserve)					215634
Earnings per share before and after extraordinary items (Not annualized)					
Basic (₹)	4.98	4.61	9.82	7.78	14.42
Diluted (₹)	4.98	4.17	9.82	7.03	13.04
Public shareholding					
- Number of shares (₹ 1 each)	81344677	83627751	81344677	83627751	84129115
- Percentage of shareholding	51.07	52.67	51.07	52.67	52.82
Promoters and promoter group Shareholding					
a) Pledged/Encumbered					
- Number of shares	6552333	8928300	6552333	8928300	7531333
- Percentage of shares (as a % of the total shareholding of promoter and	8.41	11.88	8.41	11.88	10.02
- Percentage of shares (as a % of the total share capital of the company)	4.11	5.62	4.11	5.62	4.73
b) Non-Encumbered					
- Number of shares	71384129	66223724	71384129	66223724	67620691
- Percentage of shares (as a % of the total shareholding of promoter and	91.59	88.12	91.59	88.12	89.98
- Percentage of shares (as a % of the total share capital of the company)	44.82	41.71	44.82	41.71	42.45



Notes:

1. During the quarter Cadista Holdings Inc. USA, our step down subsidiary where the company holds 82.38% equity , carrying on its generic business through a wholly owned subsidiary, Jubilant Cadista Pharmaceuticals Inc. USA , was registered with the Securities and Exchange Commission (SEC) of United States of America , under Section 12 (g) of the Securities and Exchange Control Act, United States of America .
2. The Company's operates under one reportable segment viz.Pharmaceuticals and Life Sciences Products and Services (PLSPS).
3. During the quarter the Company has opted for cash flow hedge accounting, in respect of certain transactions, under AS 30 issued by the Institute of Chartered Accountants of India. Accordingly, foreign exchange translation loss of ₹ 1483 Lacs has been debited to hedging reserve account .
4. Exceptional items include :
 - i) Amortization of Foreign Currency Monetary Item Translation Difference Account-loss/(gain) ₹ 2637 Lacs for Q2-FY 2012 and ₹ 2851 Lacs for H1-FY 2012.
 - ii) Mark to Market in respect of Currency and Interest rate swap contracts outstanding at the period end resulting in loss/(gain) amounting to ₹ 1623 Lacs for Q2 FY 2012 and ₹ 1827 Lacs for H1-FY 2012.
5. Tax Expenses(Net) is after considering the MAT Credit Entitlement ₹ 1737 Lacs for H1-FY 2012.
6. The Compensation Committee of the Board on 24th October,2011, has granted 862461 options to eligible Employees/Directors of the Company and its subsidiaries as per JLL Employee Stock Option Plan,2011. Each option shall entitle the holder to acquire 1 equity share of ₹ 1 each fully paid at ₹ 200.05, being the market price as per SEBI guidelines.There is no dilution envisaged on account of this grant.
7. Information on investors complaints for the quarter (Nos.): Opening Balance - Nil, New -23 , Disposals -23, Closing Balance - Nil.
8. The results for the corresponding quarter/six months has been recasted to give effect to the Scheme of Amalgamation & Demerger approved by Hon'ble High Court of Judicature, Allahabad during FY 2011 with effect from 1st April 2010.
9. Previous year / periods figures have been regrouped/reclassified wherever necessary.
10. The above un-audited results were subjected to limited review by the auditors of the Company, reviewed by the Audit Committee at its meeting held on 31st October, 2011 and approved by the Board of Directors at its meeting held on 1st November, 2011.